James Lillie
Patrimonio netto: 7 M $ in data 31/05/2026
Patrimonio netto: 7 M $ in data 31/05/2026
James Lillie is Chief Scientific Officer at MapLight Therapeutics, Inc. since 2019.
Formerly, Dr. Lillie was Senior Director-Biology at Scriptgen Pharmaceuticals, Inc. and Chief Scientific Officer at OvaScience, Inc. in 2018.
Dr. Lillie earned a doctorate from Harvard University and completed undergraduate studies at Wesleyan University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 07/05/2026 | 242.729 ( 0,57% ) | 7 M $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| MAPLIGHT THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/02/2019 |
| Società | Posizione | Fine |
|---|---|---|
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Direttore Tecnico/Scientifico/R&S | 07/12/2018 |
Scriptgen Pharmaceuticals, Inc.
Scriptgen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 5 |
|---|---|
Scriptgen Pharmaceuticals, Inc.
Scriptgen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops small molecule drugs | Health Technology |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wesleyan University
Wesleyan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OvaScience, Inc.
OvaScience, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of new fertility treatment options for women | Health Technology |
MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics for debilitating central nervous system disorders | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale